中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

476 records (took 0.029 seconds)

    ANTITHROMBOSIS AGENTS
    91.
    发明申请
    ANTITHROMBOSIS AGENTS 审中-公开
    抗生素代谢物

    公开(公告)号：WO1992008472A1

    公开(公告)日：1992-05-29

    申请号：PCT/US1991008516

    申请日：1991-11-14

    Applicant: COR THERAPEUTICS, INC.

    Inventor： COR THERAPEUTICS, INC. ,  SCARBOROUGH, Robert, M.

    IPC: A61K37/00

    CPC classification number: C07K14/75 ,  A61K38/00 ,  C07K14/46 ,  C07K16/18 ,  Y10S530/856

    Abstract: Platelet antiadhesives (PAA) which are useful as antithrombotics are obtainable from snake venoms which have been identified using an assay which measures the ability of the venom to inhibit ristocetin- or botrocetin-induced agglutination of platelets in the presence of von Willebrand Factor. The antiadhesives of the invention are 20-24 kd dimers of smaller peptides, or effective portions thereof. Antibodies to these antiadhesives are also prepared and are useful in assays for PAA and for screening expression libraries for PAA encoding DNA.

    Abstract translation: 可用作抗血栓药物的血小板抗粘附剂（PAA）可从蛇毒获得，蛇毒使用测定毒素在血管性血友病因子存在下抑制瑞斯托菌素或博西汀诱导血小板凝集的能力的测定法。 本发明的抗粘附剂是较小肽的20-24kD二聚体或其有效部分。 还制备了这些抗粘附剂的抗体，并且可用于PAA的测定和用于筛选编码DNA的PAA的表达文库。

    PLATELET AGGREGATION INHIBITORS
    92.
    发明申请
    PLATELET AGGREGATION INHIBITORS 审中-公开
    PLATELET聚合抑制剂

    公开(公告)号：WO1990015620A1

    公开(公告)日：1990-12-27

    申请号：PCT/US1990003417

    申请日：1990-06-15

    Applicant: COR THERAPEUTICS, INC.

    Inventor： COR THERAPEUTICS, INC. ,  SCARBOROUGH, Robert, M. ,  WOLF, David, Lawrence ,  CHARO, Israel, F.

    IPC: A61K37/62

    CPC classification number: C07K14/75 ,  A61K38/12 ,  A61K38/1703 ,  A61K38/57 ,  C07K14/46 ,  C07K14/755 ,  C07K14/78

    Abstract: An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K* -(G/Sar)-D wherein K* is a modified lysyl residue of the formula R 2 N(CH2)4CHNHCO- wherein each R is independently H, alkyl(1-6C) or at most one R is R -C=NR wherein R is H, alkyl(1-6C), phenyl or benzyl, or is NR in which each R is independently H or alkyl(1-6C) and R is H, alkyl(1-6C), phenyl or benzyl, or R -C=NR is a radical selected from the group consisting of (a), (b), (c) and (d) where m is an integer of 2-3, and each R is independently H or alkyl(1-6C); and wherein one or two (CH2) may be replaced by O or S provided said O or S is not adjacent to another heteroatom are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.

    Abstract translation: 描述了基于特异性受体结合筛选蛇毒用于存在或不存在血小板聚集抑制剂（PAI）的测定法。 使用该测定，完成了广泛的蛇毒样品中PAIs的鉴定和表征。 描述和表征了来自这些活性蛇毒中的几种的分离和纯化的PAI。 另外，缺少Arg-Gly-Asp（RGD）粘附序列但含有K * - （G / Sar）-D的PAI，其中K *是式R 1 N 2（CH 2）4 CHNHCO- 其中每个R 1独立地是H，烷基（1-6C）或至多一个R 1是R 2 -C = NR 3，其中R 2是H，烷基（1-6C） 或苯基或苄基，或为NR 4，其中每个R 4独立地为H或（1-6C）烷基，R 3为H，烷基（1-6C），苯基或苄基， 2 -C-NR 3是选自（a），（b），（c）和（d）中的基团，其中m是2-3的整数，并且每个R 5是 独立地是H或（1-6C）烷基; 并且其中一个或两个（CH 2）可以被O或S替代，条件是所述O或S不与另一个杂原子相邻，并且显示出特异性抑制纤维蛋白原或血管性血友病因子与GP IIb-IIIa的结合。

    Agents affecting thrombosis and hemostasis
    93.
    发明申请
    Agents affecting thrombosis and hemostasis 审中-公开
    影响血栓形成和止血的药物

    公开(公告)号：US20040072757A1

    公开(公告)日：2004-04-15

    申请号：US10712332

    申请日：2003-11-13

    Applicant: COR Therapeutics, Inc.

    Inventor： David L. Wolf ,  Uma Sinha

    IPC: A61K038/37

    CPC classification number: C12N9/6464 ,  A61K38/00 ,  C07K14/745 ,  C12N9/6432 ,  C12N9/647 ,  C12Y304/21006 ,  C12Y304/21069

    Abstract: Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

    Abstract translation: 短暂失活的血液因子的类似物可用于治疗以血栓形成为特征的疾病。 此外，在血清中产生活性血因子但具有延长半衰期的活化血液因子的修饰形式可用于治疗嗜血性病症。 血液因子的这些修饰形式可以是在体内缓慢脱酰基化的酰化形式。

    Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
    94.
    发明申请
    Inhibitory immunoglobulin polypeptides to human PDGF beta receptor 审中-公开
    对人PDGFβ受体的抑制性免疫球蛋白多肽

    公开(公告)号：US20030228307A1

    公开(公告)日：2003-12-11

    申请号：US10439168

    申请日：2003-05-16

    Applicant: COR Therapeutics Inc. ,  Millennium Pharmaceuticals Inc.

    Inventor： Vanitha Ramakrishnan ,  Maria Amelia Escobedo ,  Larry J. Fretto

    IPC: A61K039/395 ,  C07K016/44 ,  C07K016/28

    CPC classification number: C07K16/2863 ,  A61K38/00 ,  C07K14/71 ,  C07K2317/34 ,  C07K2317/73

    Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

    Abstract translation: 本发明涉及特异性结合人β型PDGF受体的细胞外结构域的免疫球蛋白多肽。 免疫球蛋白多肽与受体的结合抑制PDGF诱导（或刺激的）受体活化，如通过受体磷酸化和二聚化的抑制以及通过抑制PDGF介导的有丝分裂发生，趋化性和显示人PDGF型β受体的细胞的迁移所表明的 在细胞表面。 编码免疫球蛋白多肽的核酸也包含在本发明中。 免疫球蛋白多肽具有诊断和治疗用途。

    Identification of Bap-1, a protein that binds to integrin and is involved in integrin-mediated signal transduction
    96.
    发明申请
    Identification of Bap-1, a protein that binds to integrin and is involved in integrin-mediated signal transduction 审中-公开
    鉴定Bap-1，一种结合整联蛋白并参与整合素介导的信号转导的蛋白质

    公开(公告)号：US20020164698A1

    公开(公告)日：2002-11-07

    申请号：US09991888

    申请日：2001-11-26

    Applicant: COR Therapeutics, Inc.

    Inventor： Shengfeng Li ,  David R. Phillips

    IPC: C12N009/12 ,  C12P021/02 ,  C12N001/21 ,  C12N005/06 ,  C07H021/04

    CPC classification number: C07K14/47 ,  A61K38/00

    Abstract: The present invention provides the amino acid and nucleotide sequence of a protein that binds to null3 integrins, nullIIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling

    Abstract translation: 本发明提供了结合β3整联蛋白，αIIb和Src激酶并参与整联蛋白介导的信号传导的蛋白质的氨基酸和核苷酸序列。 基于该公开内容，本发明提供了用于鉴定阻断整联蛋白介导的信号传导的试剂的方法，使用阻断整联蛋白介导的信号传导来调节生物学和病理学过程的试剂的方法以及阻断整联蛋白介导的信号传导

    SYSTEMS, DEVICES, AND METHODS FOR EXTRACORPOREAL REMOVAL OF CARBON DIOXIDE
    97.
    发明申请
    SYSTEMS, DEVICES, AND METHODS FOR EXTRACORPOREAL REMOVAL OF CARBON DIOXIDE 有权

    公开(公告)号：US20250099657A1

    公开(公告)日：2025-03-27

    申请号：US18975026

    申请日：2024-12-10

    Applicant: X-Cor Therapeutics Inc.

    Inventor： Steven Paul KELLER ,  Brian Yale CHANG ,  Jayon WANG

    IPC: A61M1/16 ,  A61M1/36 ,  B01D19/00 ,  B01D61/24 ,  B01D63/02

    Abstract: Systems, devices, and methods are provided for removing carbon dioxide from a target fluid, such as, for example, blood, to treat hypercarbic respiratory failure or another condition. A device is provided including first and second membrane components for removing dissolved gaseous carbon dioxide and bicarbonate from the fluid, which can be done simultaneously. The device can be in the form of a cartridge configured for use in a dialysis system. A method of treatment is also provided, involving drawing blood from a patient and bringing the patient's blood in contact with a first membrane component having a sweep gas passing therethrough, and a second membrane component having a dialysate passing therethrough. The dialysate's composition can be selected such that charge neutrality is maintained.

    Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
    99.
    发明申请
    Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor 审中-公开
    重组C140受体，其激动剂和拮抗剂，以及编码受体的核酸

    公开(公告)号：US20030018184A1

    公开(公告)日：2003-01-23

    申请号：US10127691

    申请日：2002-04-23

    Applicant: COR THERAPEUTICS, INC.

    Inventor： Johan Sundelin ,  Robert M. Scarborough

    IPC: C07K014/715 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06

    CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K48/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/723 ,  G01N2333/726 ,  G01N2500/00

    Abstract: Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.

    Abstract translation: 编码C140细胞表面受体的核酸分子已被克隆并测序。 C140受体DNA的可用性允许重组产生可在细胞表面（包括卵母细胞）上产生的C140受体。 核酸分子可用于检测影响C140受体活性的物质，即受体激动剂或拮抗剂。 此外，阐明C140受体的结构允许设计可用于此类测定中的激动剂和拮抗剂化合物。 C140受体的可用性还允许产生与C140受体的一个或多个抗原表位特异性免疫反应的抗体。

Patent Agency Ranking